PART I Overview We are a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with serious chronic diseases and significant unmet needs. IHL-42X, our drug candidate in a pivotal Phase 2/3 clinical trial for the treatment of obstructive sleep apnea (OSA) is an oral fixed-dose combination of dronabinol and acetazolamide designed to act synergistically by targeting two different physiological pathways associated with the intermittent hypoxia and ...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-29 | 2025-06-30 | 0001213900-25-092837 | EDGAR | 87K words |
| 2024-09-30 | 2024-06-30 | 0001213900-24-082937 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-13 | 2025-12-31 | 0001213900-26-015867 | EDGAR | 18K words |
| 2025-11-14 | 2025-09-30 | 0001213900-25-110299 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001213900-25-043682 | EDGAR | — |
| 2025-02-14 | 2024-12-31 | 0001213900-25-013783 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001213900-24-098421 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001213900-24-043391 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0001213900-24-013611 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001213900-26-035161 | EDGAR | 1K words |
| 2026-03-25 | 0001213900-26-033842 | EDGAR | — |
| 2026-03-18 | 0001213900-26-029761 | EDGAR | — |
| 2026-03-17 | 0001213900-26-028661 | EDGAR | — |
| 2026-03-12 | 0001213900-26-026645 | EDGAR | — |
| 2026-03-12 | 0001213900-26-026644 | EDGAR | — |
| 2026-02-25 | 0001213900-26-020127 | EDGAR | — |
| 2026-01-29 | 0001213900-26-009160 | EDGAR | — |
| 2026-01-22 | 0001213900-26-006448 | EDGAR | — |
| 2026-01-16 | 0001213900-26-004866 | EDGAR | — |
167 total filings indexed. 148 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001873875 |
| Ticker | IXHL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.incannex.com.au |
| Listed | 2022-02-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report